Evidence & innovation
The research and patents behind IrisVision
IrisVision is grounded in real science: independent, peer-reviewed studies — including work from the Johns Hopkins Wilmer Eye Institute — and a portfolio of granted U.S. patents. Explore the clinical evidence and the technology behind IrisVision.
Peer-reviewed studies
Each study below is independent and links to the free full text. IrisVision is a low-vision aid that helps people use their remaining vision; it is not a cure or medical treatment.
-
PLOS ONE 2025 Open access
Comparison of visual function analysis of people with low vision using three different models of augmented reality devices
Across people with low vision, the majority of visual functions improved with IrisVision, including statistically significant gains in distance and near visual acuity and contrast sensitivity — outperforming a comparison device.
Envision Research Institute; SUNY College of Optometry; Smith-Kettlewell Eye Research Institute PMID 41060945
-
Optometry and Vision Science 2024 Open access
Comparative effectiveness between two types of head-mounted magnification modes using a smartphone-based virtual display
In a randomized home trial of 88 people with low vision, both IrisVision magnification modes — full-field and virtual bioptic — produced large, statistically significant improvements in self-reported reading ability (Cohen's d = 0.82–1.00).
SUNY College of Optometry; Marshall B. Ketchum University; Wilmer Eye Institute, Johns Hopkins University School of Medicine; University of California, Berkeley PMID 38551973
-
Clinical Optometry 2023 Open access
At-Home Trial of Four Different Head-Mounted Displays in Visual Rehabilitation of People with Stargardt Disease
In people with Stargardt disease, IrisVision Live improved distance and near visual acuity and reading ability after home use.
Copenhagen University Hospital Rigshospitalet-Glostrup; University of Copenhagen PMID 38046087
-
Translational Vision Science & Technology 2019 Open access
Preliminary Evaluation of Two Digital Image Processing Strategies for Head-Mounted Magnification for Low Vision Patients
In an at-home clinical outcome study, IrisVision produced large, statistically significant improvements in reading ability (Cohen's d = 1.28) and visual-information tasks (d = 1.11), with participants rating the system 7.1 out of 10.
Wilmer Eye Institute, Johns Hopkins University School of Medicine; University of California, Berkeley PMID 30834171
Patents
IrisVision's technology is protected by a portfolio of granted U.S. patents covering multi-modal vision enhancement, magnification, contrast-sensitivity compensation, and condition-specific processing.
- US 11,372,479 B2 Multi-Modal Vision Enhancement System
- US 11,144,119 B2 Methods and Systems for Generating a Magnification Region in Output Video Images
- US 11,475,547 B2 Methods and Apparatus for Contrast Sensitivity Compensation
- US 10,963,999 B2 Methods and Apparatus for Contrast Sensitivity Compensation
- US 11,546,527 B2 Methods and Apparatuses for Compensating for Retinitis Pigmentosa
- US 10,444,833 B2 Methods and Apparatus for Vision Enhancement
- US 10,146,304 B2 Methods and Apparatus for Vision Enhancement
Patent-pending
Additional published applications extend the portfolio to remote vision testing, clinician management of head-mounted devices, and further vision-enhancement methods.
- US 2022/0160223 A1 · Patent pending Methods and Systems for Evaluating Vision Acuity and/or Conducting Visual Field Tests in a Head-Mounted Vision Device
- US 2022/0171456 A1 · Patent pending Method and System for Remote Clinician Management of Head-Mounted Vision Assist Devices
- US 2022/0043513 A1 · Patent pending Methods and Apparatus for Vision Enhancement